Theravance Biopharma Inc (TBPH.OQ)
TBPH.OQ on NASDAQ Stock Exchange Global Market
27.65USD
4:00pm EDT
27.65USD
4:00pm EDT
Change (% chg)
$0.81 (+3.02%)
$0.81 (+3.02%)
Prev Close
$26.84
$26.84
Open
$26.98
$26.98
Day's High
$28.16
$28.16
Day's Low
$26.90
$26.90
Volume
50,733
50,733
Avg. Vol
72,936
72,936
52-wk High
$35.83
$35.83
52-wk Low
$21.27
$21.27
About
Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product... (more)
Overall
| Beta: | 1.89 |
| Market Cap(Mil.): | $1,514.81 |
| Shares Outstanding(Mil.): | 55.10 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| TBPH.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 28.12 | 30.20 |
| EPS (TTM): | -4.89 | -- | -- |
| ROI: | -63.76 | 13.07 | 12.77 |
| ROE: | -188.52 | 15.04 | 14.92 |
BRIEF-Theravance Expects To Report Data From Phase 2A Study In nOH Patients By July End
* THERAVANCE BIOPHARMA TO HOST KEY OPINION LEADER EVENT FOCUSED ON THE UNMET MEDICAL NEED IN THE TREATMENT OF NEUROGENIC ORTHOSTATIC HYPOTENSION
BRIEF-Theravance Biopharma Q4 Revenue $4.5 Million
* THERAVANCE BIOPHARMA, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Competitors
| Price | Chg | |
|---|---|---|
| Merck & Co., Inc. (MRK.N) | $68.85 | +1.48 |
| The Medicines Company (MDCO.OQ) | $39.53 | -0.25 |
| GlaxoSmithKline plc (GSK.L) | 1,610.00 | +19.60 |
| AstraZeneca plc (AZN.L) | 5,936.00 | -6.00 |
| Novartis AG (NOVN.S) | CHF81.72 | +0.86 |
Estimates